Comments
Emkay Global
HDFC Life Insurance Company (Buy)
Target: ₹870
CMP: ₹663.60
HDFC Life has reported VNB (value of new business) margins of 26.2 per cent (+180 bps y-o-y) in Q1FY22. The share of individual protection products declined by about 4 per cent y-o-y as the share of ULIPs rose in overall AUM. The company witnessed disruption in business activities in May; however, other products like annuity and credit life performed well.
HDFC Life saw a steep rise in death claims, with peak claims in the second Covid wave at about 3-4 times of peak claims in the first wave. The company cleared approximately 70,000 claims in Q1, with gross/net claims amounting to ₹1,600 crore/₹960 crore. The company has created an additional reserve of ₹700 crore; however, near-term uncertainties persist.
HDFC Life continues to focus on the diversified distribution channel to create a balanced product mix for optimum profitability. Its balanced product mix provides cushion against business cycles while taking advantage of the under-penetrated protection market.
We expect the trend in margins to remain stable with a balanced product mix and a gradual rise in the share of protection and annuity plans along with increasing penetration in deeper geographies. We roll forward our target price to September 2022 and maintain ‘Buy’ with a revised TP of ₹870 (₹848 previously).
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.